科研之友
微信
新浪微博
Facebook
分享链接
摘要
Despite surgical improvements and pharmacological advances,management of late-stage gastric cancer patients,especially those with hepatic metastasis remains challenging [1-3].Although nationwide registry data from SEER (Surveillance,Epidemiology,and End Results)[4] and the Nordic database [5] in Western countries have provided epidemiological information for patients with gastric cancer liver metastasis (GCLM),little is known about the detailed clinical characteristics.Recently,emerging evidence has indicated that selective implementation of systemic chemotherapy,immune checkpoint inhibitor (ICI) therapy,surgical resection,
- 单位
